Oramed Pharmaceuticals (XTAE:ORMP) Cyclically Adjusted FCF per Share: ₪-1.85 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:ORMP Oramed Pharmaceuticals Inc XTAE:ORMP
23 GF Score
Price ₪12.72
! 5 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals Cyclically Adjusted FCF per Share?

Oramed Pharmaceuticals XTAE:ORMP -5.78% 23 Cyclically Adjusted FCF per Share is ₪-1.85 as of Mar. 2026. GuruFocus rates XTAE:ORMP with a GF Score™ of 23/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Oramed Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was ₪-0.212. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₪-1.85 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 3.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -2.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Oramed Pharmaceuticals was 3.30% per year. The lowest was -11.30% per year. And the median was -8.45% per year.

As of today (2026-08-04), Oramed Pharmaceuticals's current stock price is ₪12.72. Oramed Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ₪-1.85. Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Oramed Pharmaceuticals  (XTAE:ORMP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Oramed Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Oramed Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.77 -2.00 -2.17 -2.07 -1.77

Oramed Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.14 -1.86 -1.88 -1.77 -1.85

XTAE:ORMP vs CAMP, PYXS, ALEC: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


XTAE:ORMP
23GF Score
Oramed Pharmaceuticals Inc XTAE:ORMP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oramed Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.212/330.2130*330.2130
=-0.212

Current CPI (Mar. 2026) = 330.2130.

Oramed Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201605 -0.518 240.229 -0.712
201608 1.575 240.849 2.159
201611 0.345 241.353 0.472
201702 -0.670 243.603 -0.908
201705 -0.540 244.733 -0.729
201708 -0.464 245.519 -0.624
201711 -0.583 246.669 -0.780
201802 -0.732 248.991 -0.971
201805 -0.798 251.588 -1.047
201808 -0.867 252.146 -1.135
201811 -0.722 252.038 -0.946
201902 -0.329 252.776 -0.430
201905 -0.639 256.092 -0.824
201908 -0.570 256.558 -0.734
201911 -0.522 257.208 -0.670
202002 -0.620 258.678 -0.791
202005 -0.440 256.394 -0.567
202008 -0.327 259.918 -0.415
202011 -0.828 260.229 -1.051
202102 -0.370 263.014 -0.465
202105 -0.574 269.195 -0.704
202108 -0.566 273.567 -0.683
202111 -0.573 277.948 -0.681
202203 -0.722 287.504 -0.829
202206 -0.668 296.311 -0.744
202209 -0.184 296.808 -0.205
202212 -0.646 296.797 -0.719
202303 -0.437 301.836 -0.478
202306 -0.201 305.109 -0.218
202309 -0.055 307.789 -0.059
202312 -0.104 306.746 -0.112
202403 -0.108 312.332 -0.114
202406 0.152 314.175 0.160
202409 -0.529 315.301 -0.554
202412 -0.144 315.605 -0.151
202503 -0.260 319.799 -0.268
202506 -0.253 322.561 -0.259
202509 -0.267 324.800 -0.271
202512 -0.020 324.054 -0.020
202603 -0.212 330.213 -0.212

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ₪-1.85 mean?
Oramed Pharmaceuticals (XTAE:ORMP) has a Cyclically Adjusted FCF per Share of ₪-1.85 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Oramed Pharmaceuticals' current Cyclically Adjusted FCF per Share is ₪-1.85. Overall, Oramed Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' Cyclically Adjusted FCF per Share compare to CAMP and PYXS?
Oramed Pharmaceuticals' Cyclically Adjusted FCF per Share of ₪-1.85 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current Cyclically Adjusted FCF per Share is ₪-1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (XTAE:ORMP) has a current Cyclically Adjusted FCF per Share of ₪-1.85. The current Cyclically Adjusted FCF per Share is ₪-1.85. Oramed Pharmaceuticals' overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Oramed Pharmaceuticals (XTAE:ORMP), the current Cyclically Adjusted FCF per Share is ₪-1.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Other Exchanges ORMP:USAOJU1:Germany
Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
23GF Score

Get the complete analysis for XTAE:ORMP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪12.72
Price